Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Evaluating multi-slice ptychography tomography for X-ray imaging.

Optics express·2026

Same author

Triple threat bismuth peptide imaging in cells.

Chemical science·2026

Same author

The nature of thallium crystals in Brassica oleracea (kale): a synchrotron multi-technique investigation.

Metallomics : integrated biometal science·2026

Same author

Multifunctional bending magnet beamline with a capillary optic for X-ray fluorescence studies of metals in tissue sections.

Journal of synchrotron radiation·2026

Same author

XFM and HERFD-XAS studies of selenium in tissues and whole blood from mice supplemented with potentially therapeutic selenocompounds.

Redox report : communications in free radical research·2026

Same author

EXAFS Analysis of Ru265 and Ru360 in Human Blood.

Inorganic chemistry·2026

Same journal

Library Docking for Cannabinoid-2 Receptor Ligands.

Journal of medicinal chemistry·2026

Same journal

Charting New Territory: Systematic Evaluation of the Drug Potential of <i>N</i>-Trifluoromethyl Amides, Ureas & Carbamates.

Journal of medicinal chemistry·2026

Same journal

Red-Light-Triggered <i>In Vitro</i> and <i>In Vivo</i> Photocatalytic Cancer Therapy with Polypyridyl Os(II) Photocatalysts.

Journal of medicinal chemistry·2026

Same journal

Novel Selenium-Containing Small Molecule PD-L1 Inhibitors: Design, Synthesis, and Evaluation of the Antitumor Activity.

Journal of medicinal chemistry·2026

Same journal

HsClpP-Engaging Selective Mitochondrial Pan-PDK Degraders for Cancer Therapy.

Journal of medicinal chemistry·2026

Same journal

Rational Development of Activatable Prodrugs of the GSTP1 Inhibitor NBDHEX: Turn-On NIR Fluorogenic Drug Delivery with Selective Anticancer Activity.

Journal of medicinal chemistry·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jul 19, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Optimizing Arsenic Therapy by Selectively Targeting Leukemia Cells.

Judith A Carrall¹, Wilford Lie¹, Jacob M Lambert^1,2

¹School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong 2522, New South Wales, Australia.

Journal of Medicinal Chemistry

|August 18, 2023

Summary

This summary is machine-generated.

Researchers developed novel arsenic-peptide complexes to target leukemia, significantly reducing toxicity to healthy cells. This breakthrough offers a more effective and safer treatment for leukemia patients.

More Related Videos

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Experiment Videos

Last Updated: Jul 19, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Modeling Chemotherapy Resistant Leukemia In Vitro

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Area of Science:

Oncology
Nanotechnology
Medicinal Chemistry

Background:

Arsenic trioxide is approved for acute promyelocytic leukemia.
Arsenic shows potential in other leukemias but has toxic effects on normal cells.
Targeted drug delivery can mitigate arsenic's toxicity.

Purpose of the Study:

To design and develop tumor-homing peptide complexes of arsenic.
To create a targeted arsenic therapeutic agent for leukemia.
To reduce the dosage and side effects of arsenic-based cancer therapy.

Main Methods:

Synthesis and characterization of novel arsenic-peptide complexes.
Stability studies of the synthesized complexes.
In vitro evaluation of cytotoxicity against leukemia and human blood cells.

Main Results:

A new class of arsenic-peptide complexes targeting leukemia was successfully synthesized.
The most stable complex demonstrated 1000-fold greater toxicity to leukemia cells compared to human blood cells.
These findings suggest significant potential for targeted arsenic therapy.

Conclusions:

Arsenic-peptide complexes offer a promising strategy for targeted leukemia treatment.
This approach may lead to reduced systemic toxicity and improved patient outcomes.
Further in vivo studies are warranted to validate the therapeutic potential.